CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart...
Phase 2
Sevilla, Spain and 64 other locations
tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease...
Sevilla, Spain and 44 other locations
Evaluation of TAVR using the NAVITOR valve in a Global Investigation.
Sevilla, Spain and 37 other locations
with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac...
Phase 3
Sevilla, Spain and 191 other locations
of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart...
Phase 2
Sevilla, Spain and 51 other locations
of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart...
Phase 2
Sevilla, Spain and 62 other locations
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...
Phase 3
Sevilla, Andalucía, Spain and 851 other locations
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardio...
Phase 3
Sevilla, Spain and 588 other locations
cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb...
Phase 3
Sevilla, Andalucia, Spain and 617 other locations
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease...
Phase 3
Sevilla, Andalucía, Spain and 736 other locations
Clinical trials
Research sites
Resources
Legal